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Abstract: BACKGROUND The ancient drug dapsone has antimicrobial and anti-inflammatory features.
In dermatology, dapsone is primarily used for neutrophil-dominant skin diseases. However, real-life data
assessing the long-term efficacy of dapsone across multiple dermatological diseases is missing. -Objectives:
To determine the efficacy and safety of dapsone in patients with inflammatory skin diseases treated at the
Department of Dermatology of the University Hospital Zurich. METHODS The hospital database was
searched for patients treated with dapsone in the last 20 years (from January 1, 1998, to December 31,
2017). Overall, 175 patients were included in our study. RESULTS Thirty-four patients received dapsone
for eosinophilic dermatoses, 82 for neutrophilic dermatoses and 59 for other dermatoses. After 3 months,
8% of all patients reached complete remission, 40.6% showed improvement, 30.3% had stable disease,
and only 9.1% had disease progression. Final treatment evaluation revealed complete response in 13.2%,
disease improvement in 47.4%, stable disease in 25.7% and disease progression in only 12.0%. Patients
who showed remission or improvement after 3 months were significantly older than patients with stable
or progressive disease. In addition, remission after 3 months was associated with a significantly lower
dose of dapsone compared to improvement only. Hemolysis was the most common adverse event (21.7%).
CONCLUSIONS Our data show that dapsone is a valid treatment option in various dermatological
diseases, leading to a favorable response in the vast majority of patients. In addition, it is well tolerated,
safe and inexpensive. Randomized, controlled trials are needed to further elucidate the role of this
high-potential drug.
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Abstract
Background: The ancient drug dapsone has antimicrobial 
and anti-inflammatory features. In dermatology, dapsone is 
primarily used for neutrophil-dominant skin diseases. How-
ever, real-life data assessing the long-term efficacy of dap-
sone across multiple dermatological diseases is missing. 
 Objectives: To determine the efficacy and safety of dapsone 
in patients with inflammatory skin diseases treated at the 
Department of Dermatology of the University Hospital Zu-
rich. Methods: The hospital database was searched for pa-
tients treated with dapsone in the last 20 years (from January 
1, 1998, to December 31, 2017). Overall, 175 patients were 
included in our study. Results: Thirty-four patients received 
dapsone for eosinophilic dermatoses, 82 for neutrophilic 
dermatoses and 59 for other dermatoses. After 3 months, 8% 
of all patients reached complete remission, 40.6% showed 
improvement, 30.3% had stable disease, and only 9.1% had 
disease progression. Final treatment evaluation revealed 
complete response in 13.2%, disease improvement in 47.4%, 
stable disease in 25.7% and disease progression in only 
12.0%. Patients who showed remission or improvement af-
ter 3 months were significantly older than patients with sta-
ble or progressive disease. In addition, remission after 
3 months was associated with a significantly lower dose of 
dapsone compared to improvement only. Hemolysis was 
the most common adverse event (21.7%). Conclusions: Our 
data show that dapsone is a valid treatment option in various 
dermatological diseases, leading to a favorable response in 
the vast majority of patients. In addition, it is well tolerated, 
safe and inexpensive. Randomized, controlled trials are 
needed to further elucidate the role of this high-potential 
drug. © 2019 S. Karger AG, Basel
Introduction
The sulfone dapsone (4,4’-diaminodiphenylsulfone) is 
an aniline derivative and was first synthesized in 1908, but 
its medical use was only later discovered in 1937 [1]. In 













































































coccal infections in mice [2, 3] and later on in the treat-
ment of sexually transmitted infections, such as gonor-
rhea [1]. Over time, it gained significance as a steroid-
sparing treatment option for several skin diseases, such as 
bullous pemphigoid, linear IgA dermatosis and dermati-
tis herpetiformis [2].
The chemical structure of dapsone encompasses a sul-
fur atom, covalently bound to 2 carbon atoms. Upon oral 
intake, it enters the enterohepatic circulation and is ab-
sorbed in the gut with bioavailability reaching 86%. Dap-
sone is eliminated primarily as metabolites in the urine, 
while only a small amount is eliminated in the feces [1, 4]. 
Hepatic metabolization occurs through acetylation and 
hydroxylation [1]. Dapsone passes the brain-blood bar-
rier as well as the placenta and can be found in breast milk 
[5, 6], leading to fetal cyanosis [7].
Dapsone has antimicrobial, antiprotozoal and anti-in-
flammatory properties [8]. It inhibits the synthesis of di-
hydrofolic acid [1], thus inhibiting neutrophil influx 
(chemotaxis) and tissue injury [9], while suppressing se-
cretion of inflammatory cytokines [10]. Accordingly, in 
dermatology, dapsone is classically used for skin diseases 
with increased neutrophil and eosinophil infiltration 
[11]. 
Dapsone has been successfully used since the 1930s, 
yet no randomized, controlled, double-blind studies have 
been performed. 
The objective of our study was to determine the effi-
cacy and safety of dapsone in patients with inflamma-
tory skin diseases, treated at the Department of Derma-
tology of the University Hospital Zurich during the last 
20 years. 
Methods
For further details, see the supplementary material (for all 
online supplementary material, see www.karger.com/
doi/10.1159/000502256) (Fig. 1).
Results
From 207 patients who received dapsone between 
1998 and 2017 in our center, 175 patients met the inclu-
sion criteria. There was a slight male predominance (91 
men vs. 84 women). The average age at treatment initia-
tion was 48.2 ± 17.9 years, the youngest patient analyzed 
was 18, the oldest 89 (Table 1).
The dosage administered ranged from 25 to 200 mg. 
The daily dose received by the majority of patients (n = 
93) was 100 mg. The median duration of dapsone intake 
was 4 months, the mean 12 ± 20 (0.2–132) months. Poor 
adherence was documented in 12% (n = 21) of all patients 
(Table 1).
Thirty-four patients received dapsone for primarily 
eosinophilic dermatoses, 82 for primarily neutrophilic 
dermatoses and 59 for “other dermatoses” (Table 2). 
Search in the hospital information
system for patients being treated with
dapsone from 1998 to 2017 (n = 207)
 Exclusion of patients under 18 years
 according to ethical commission (n = 7)
 Exclusion of patients with no follow-up
 visits (n = 25)
Analysis of data (n = 175)
Fig. 1. Flow chart of the Methods: patient 
selection for analysis. Participant inclusion 
and exclusion flow diagram. Exclusion cri-
teria encompassed age younger than 18 
years. 
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The most common previous systemic treatments in-
cluded immunosuppressive drugs (n = 117), steroids (n = 
78), antibiotics (n = 54) and antihistamines (n = 42). Top-
ical steroids were the most prevalent previously used top-
icals (n = 84). In most cases, dapsone was the third line of 
treatment (n = 62). The most common concomitant 
treatment were systemic steroids (n = 45) and topical ste-
roids (n = 70; Table 3).
Outcome
After 3 months, 8% (n = 14) of all patients reached 
complete remission and 40.6% (n = 71) showed im-
provement. In 30.3% (n = 53) the disease proved to be 
stable and in 9.1% (n = 16) a progression of disease was 
observed (Fig. 2a). Complete remission was reached in 
patients with dermatitis herpetiformis (n = 3), linear 
IgA dermatosis (n = 3), urticarial vasculitis (n = 3), hi-
dradenitis suppurativa (n = 2), Wells syndrome (n = 1), 
pyoderma gangrenosum (n = 1) and folliculitis decal-
vans (n = 1).
When the last data documented were analyzed, 23 
(13.2%) patients showed full remission, 83 (47.4%) im-
provement of disease, 45 (25.7%) stable disease and 21 
(12.0%) progression of disease. No data on outcome were 
found in 3 (1.7%) cases (Fig. 2b).
There was no statistical difference in outcome regard-
ing the type of disease (p = 0.0769; Fig. 3a). Patients who 
showed remission or improvement after 3 months were 
significantly older (53 ± 19 vs. 43 ± 15; p = 0.003) than 
patients with stable disease or progression of disease 
(Fig. 3b). Gender was not associated with treatment re-
sponse in the first 3 months (p = 0.9429; Fig. 3c). Patients 
who had a remission after 3 months, had used a signifi-
cantly lower dose of dapsone compared to the improve-
ment group (89.3 ± 45.7 mg vs. 117.3 ± 33.7 mg; p = 
0.006). Patients, where improvement of symptoms was 
seen, had significantly higher dosages compared to the 
group who reported a stable disease (117.3 ± 33.7 vs. 
102.8 ± 31.7 mg; p = 0.0304). No statistical significance 
regarding dosage was found in patients who had a stable 
disease/progression of disease as well as when the remis-
sion group/improvement group was compared to the 
stable disease/progression of disease group (p = 0.086; 
Fig. 3d). The level of methemoglobin was not associated 
with treatment response in the first 3 months (p = 0.086; 
Fig. 3e).
Safety
Hemolysis was the most common adverse event and 
seen in 38 patients (21.7%). Common side effects includ-
ed symptoms of hemolysis (methemoglobinemia). Glu-
cose-6-phosphate dehydrogenase (G6PD) was physio-
logical in 124 patients. In 21 it even occurred to be in-
creased. Only 1 patient was treated despite a decrease in 
G6PD. No data were available for 31 patients. Hepatopa-
thy (n = 20, 11.4%) and nephropathy (n = 19, 10.8%) were 
commonly seen side effects. 
In our cohort, and as previously described, we also 
found patients where transaminases and glomerular fil-
























Acne vulgaris and other acne types
Acne and hidradenitis suppurativa














































































































































tration rate increased [12]. Leukopenia and thrombocy-
topenia [13], nonspecific interstitial pneumonia and pe-
ripheral neuropathy [14] have been described but oc-
curred only in a limited number in our patient cohort 
(Table 4).
Discussion
In this study, we analyzed the efficacy and safety of 
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In many dermatoses, dapsone is still a standard of 
treatment, which is supported by our data. In the long 
term, the majority of all patients had either remission or 
improvement of disease, emphasizing its high efficacy. 
This is especially noteworthy, given the fact that dapsone 
was usually the third line of treatment. It has to be taken 
into account that our analysis includes data from the last 
20 years when dapsone was also used for diagnoses, for 
which it is not utilized today (e.g., chronic urticaria). 
Also, off-label treatments were included. 
A limitation of our study is the retrospective, mono-
centric design. Additionally, weight was not routinely 
documented and therefore not analyzed. Topical use of 
dapsone (approved in the US for acne vulgaris) was not 
addressed, as it is not available in Europe. Dapsone can 
be used for many infectious diseases (leprosy, malaria, 
actinomycetoma, etc.) [15], but as those patients are rare-
ly seen in Switzerland, we did not have any cases to assess 
its efficacy in those particular diseases. The wide variety 
of dermatoses analyzed presents another limitation of 
this study. 
In our real-world data, we did not identify that gender 
affected treatment outcome. However, older patients sig-
nificantly showed better responses. The reasons for this 
observation remain unclear and may be associated with 
the impact of aging on the immune system. Even though 
dose escalation in our patients was routinely performed, 
our overall data did not show a superior treatment re-
sponse among those receiving a higher dose. According-
ly, even though we did not take the patient’s weight into 
account, a dose escalation beyond 150 mg daily seems un-
likely to lead to treatment success. 
Overall, dapsone was a safe medication, even though 
hemolysis was found in 21.7% (never higher than CTC 
Grade 2) and was in no case the reason for termination of 
therapy. In most cases patients receive vitamin E to re-
duce symptoms of methemoglobinemia [16, 17], as it was 
the case in our cohort. Puavilai et al. [18] show a similar 
incidence of hemolysis in patients treated with dapsone 
for leprosy (20%). 
Under dapsone, hypersensitivity syndrome (dapsone 
syndrome) has been reported to develop in approximate-
Fig. 3. Outcomes. * p < 0.05, ** p < 0.01; ns, nonsignificant. a Dis-
ease category and outcome. There was no statistical difference 
whether primarily eosinophilic, neutrophilic or “other” dermato-
ses were treated (p = 0.0769). b Age. Patients who showed remis-
sion or improvement after 3 months were significantly older than 
patients who had a stable disease or progression of disease (53 ± 19 
vs. 43 ± 15 years; p = 0.003). c Outcome and gender. There was no 
significant difference in outcome when stratified for gender (p = 
0.9429). d Outcome and dosage. Patients received dapsone in dif-
ferent dosages (25–200 mg). In the group that showed complete 
response to treatment, the dosage was lower than compared to the 
patients where only “improvement” was observed. There was no 
significant difference in dosage between patients with stable dis-
ease and those who progressed under dapsone therapy. e Outcome 
and highest methemoglobin. There was no significant difference 
between the highest methemoglobin reached and treatment re-










































Fig. 2. a Treatment evaluation after 3 months. In the majority of all cases, an improvement under dapsone was seen after 3 months. b 
Long-term treatment success. Treatment response from baseline to the end of therapy was evaluated. In the majority of patients, a ben-
eficial therapeutic response was observed. 
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ly 0.5–3.6% of all cases [15]. It is characterized by the clin-
ical triad of fever, rash and systemic involvement (mostly 
liver and hematological system). It occurs usually be-
tween 4 and 6 weeks after drug intake [15]. Fatal out-
comes have been reported [12, 19] and mortality is ob-
served in about 9.9% of all hypersensitivity syndrome cas-
es [15]. An association was found with the locus 
HLA-B*13: 01 among leprosy patients [15]. While HLA-
B*13: 01 is hardly found among Europeans and Africans, 
it occurs in up to 20% of Asians [15]. In our cohort, 4 
patients (2.3%) developed hypersensitivity syndrome, 
and no fatality occurred.
In summary, our data show that dapsone is a useful 
and efficient systemic treatment in dermatology. We sug-
gest that daily dosage should be limited up to 150 mg. 
Even though treatment with dapsone is safe, blood checks 
ought to be performed regularly to detect hemolysis early. 
Patients should be informed about hypersensitivity syn-
drome, and patients of Asian descent profit from screen-
ing for HLA-B*13: 01.
Key Message
Real-world data show high efficacy and a low number of ad-
verse events.
Statement of Ethics
The authors have no ethical conflicts to declare.
Disclosure Statement
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Table 4. Adverse events under treatment with dapsone





























































Problems with glycemic control
Pain in the region of the kidneys, pollakisuria
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